AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37380211 — intervention group
Group type: EXPERIMENTAL
Intervention: TESLA-G
Number of subjects: 50
Study 37380212 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient management
Number of subjects: 0
Study 37380212 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care management
Number of subjects: 0
Study 37380212 — intervention group
Group type: COMPARATOR
Intervention: Hospital admission
Number of subjects: 0
Study 37380226 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter edge-to-edge repair (TEER) plus guideline-directed medical therapy (GDMT)
Number of subjects: 614
Study 37380226 — intervention group
Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT) alone
Number of subjects: 614
Study 37380226 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter edge-to-edge repair (TEER) with anticoagulation
Number of subjects: 614
Study 37380226 — intervention group
Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT) alone without anticoagulation
Number of subjects: 614
Study 37380301 — intervention group
Group type: EXPERIMENTAL
Intervention: Goflikicept
Number of subjects: 22
Study 37380301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 37380364 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat (oral hypoxia-inducible factor prolyl hydroxylase inhibitor), administered three times weekly in-center for 24 weeks.
Number of subjects: 283
Study 37380519 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 0
Study 37380568 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Blood Management (PBM)
Number of subjects: 1201817
Study 37380598 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved trajectory
Number of subjects: 0
Study 37380598 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Stable trajectory
Number of subjects: 0
Study 37380625 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous pulse oximetry (cSpO) monitoring
Number of subjects: 0
Study 37380625 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37380711 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma corticosteroid levels in the third trimester
Number of subjects: 1503
Study 37380749 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent body fat in the POPF group (26.90)
Number of subjects: 143
Study 37380749 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 143
Study 37380749 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic duct < 3 mm
Number of subjects: 143
Study 37380749 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent body fat
Number of subjects: 143
Study 37380749 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent body fat ≥ 35%
Number of subjects: 143
Study 37380821 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion using vascular access button (VAB) technology for AZD5991
Number of subjects: 0
Study 37380821 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 37380901 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipeline Embolization Devices (PEDs)
Number of subjects: 52
Study 37380905 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA and NIRS/IVUS imaging
Number of subjects: 69
Study 37380905 — intervention group
Group type: COMPARATOR
Intervention: CCTA
Number of subjects: 69
Study 37381014 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline retinal oximetry
Number of subjects: 41
Study 37381014 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography angiography (OCT-A)
Number of subjects: 41
Study 37381014 — intervention group
Group type: EXPERIMENTAL
Intervention: Microperimetry
Number of subjects: 41
Study 37381691 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp hair regrowth (meaningful regrowth, SALT score ≤20)
Number of subjects: 0
Study 37381691 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp hair regrowth (meaningful regrowth)
Number of subjects: 0
Study 37381691 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp hair regrowth at Week 36
Number of subjects: 0
Study 37381691 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate scalp hair regrowth
Number of subjects: 0
Study 37381988 — intervention group
Group type: EXPERIMENTAL
Intervention: rNAPc2 (lower or higher dose)
Number of subjects: 160
Study 37381988 — intervention group
Group type: EXPERIMENTAL
Intervention: rNAPc2
Number of subjects: 160
Study 37381988 — intervention group
Group type: COMPARATOR
Intervention: Heparin (standard of care)
Number of subjects: 160
Study 37382155 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA vaccines BNT162b2 (Pfizer/BioNTech), mRNA1273 (Moderna) in two and three-dose regimens
Number of subjects: 0
Study 37382155 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent mRNA vaccines
Number of subjects: 0
Study 37382155 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualization and adjustment of immunosuppressive drugs
Number of subjects: 0
Study 37382370 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-impact laparoscopy (LIL)
Number of subjects: 50
Study 37382370 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopy
Number of subjects: 50
Study 37382408 — intervention group
Group type: EXPERIMENTAL
Intervention: Access flap with xenograft and collagen membrane (test)
Number of subjects: 40
Study 37382408 — intervention group
Group type: COMPARATOR
Intervention: Access flap (control)
Number of subjects: 40
Study 37382408 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 37382794 — intervention group
Group type: EXPERIMENTAL
Intervention: FM-ACT (self-guided digital acceptance and commitment therapy) for 12 weeks, n=39
Number of subjects: 67
Study 37382794 — intervention group
Group type: COMPARATOR
Intervention: FM-ST (digital symptom tracking) for 12 weeks, n=28
Number of subjects: 67
Study 37382825 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 501
Study 37382891 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (measured by steps taken per day)
Number of subjects: 419
Study 37382891 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time (hours per day)
Number of subjects: 419
Study 37382913 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative Indocyanine Green Angiography (ICGA)
Number of subjects: 10
Study 37382961 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose
Number of subjects: 1132
Study 37382961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1132
Study 37382961 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose and Placebo
Number of subjects: 1132
Study 37382971 — intervention group
Group type: EXPERIMENTAL
Intervention: Norovirus infection management in kidney transplant recipient
Number of subjects: 1
Study 37383243 — intervention group
Group type: EXPERIMENTAL
Intervention: imipenem/cilastatin/relebactam (IMI/REL)
Number of subjects: 0
Study 37383243 — intervention group
Group type: COMPARATOR
Intervention: piperacillin/tazobactam
Number of subjects: 0
Study 37383243 — intervention group
Group type: EXPERIMENTAL
Intervention: normal renal function, APACHE II score <15, no vasopressor use, no bacteremia at baseline
Number of subjects: 0
Study 37383243 — intervention group
Group type: EXPERIMENTAL
Intervention: vasopressor use, renal impairment, bacteremia at baseline, APACHE II scores ≥15
Number of subjects: 0
Study 37383290 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir/Levonorgestrel (TFV/LNG) intravaginal ring
Number of subjects: 27
Study 37383290 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir (TFV) intravaginal ring
Number of subjects: 27
Study 37383290 — intervention group
Group type: COMPARATOR
Intervention: Placebo intravaginal ring
Number of subjects: 27
Study 37383763 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard opioid prescription (ten 5 mg tablets oxycodone provided preoperatively)
Number of subjects: 82
Study 37383763 — intervention group
Group type: COMPARATOR
Intervention: Restricted opioid prescription (opioid prescription provided only upon patient request postoperatively)
Number of subjects: 82
Study 37383763 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 82
Study 37383995 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat soya blend plus (WSB+) during pregnancy and first six months of lactation, and lipid-based nutrient supplement - medium-quantity (LNS-MQ) between 6-23 months of age.
Number of subjects: 2030
Study 37383995 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nutritional supplementation).
Number of subjects: 2030
Study 37384109 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic and herbal supplement taken twice a day for 1 month
Number of subjects: 0
Study 37384109 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 0
Study 37384278 — intervention group
Group type: EXPERIMENTAL
Intervention: Microburst VNS in addition to standard anti-seizure medications
Number of subjects: 0
Study 37384390 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Messaging (AM) intervention
Number of subjects: 800
Study 37384390 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 800
Study 37384392 — intervention group
Group type: EXPERIMENTAL
Intervention: Message-based psychotherapy (n=46)
Number of subjects: 83
Study 37384392 — intervention group
Group type: COMPARATOR
Intervention: Video-based psychotherapy (n=37)
Number of subjects: 83
Study 37384412 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib 100 mg twice daily for 6 weeks
Number of subjects: 10
Study 37384434 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential training in emotional processing skills
Number of subjects: 0
Study 37384434 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37384482 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure
Number of subjects: 119
Study 37384482 — intervention group
Group type: COMPARATOR
Intervention: Concurrent Treatment of PTSD and Substance Use Disorders using Seeking Safety
Number of subjects: 119
Study 37384482 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Treatment of PTSD and Substance Use Disorders (both interventions)
Number of subjects: 119
Study 37384600 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based health education intervention
Number of subjects: 41
Study 37384671 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mobilization, mobile health teams offering MNCH and immunization services, engagement of the private sector, testing of the Sehat Nishani app for 12 months
Number of subjects: 0
Study 37384671 — intervention group
Group type: EXPERIMENTAL
Intervention: Sehat Nishani app
Number of subjects: 0
Study 37384799 — intervention group
Group type: EXPERIMENTAL
Intervention: Pf 7G8 clone CHMI
Number of subjects: 0
Study 37384848 — intervention group
Group type: EXPERIMENTAL
Intervention: Zipalertinib at various dose levels (30, 45, 65, 100, and 150 mg orally twice a day)
Number of subjects: 73
Study 37384848 — intervention group
Group type: EXPERIMENTAL
Intervention: Zipalertinib at 100 mg twice a day
Number of subjects: 73
Study 37384848 — intervention group
Group type: EXPERIMENTAL
Intervention: Zipalertinib
Number of subjects: 73
Study 37384853 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring
Number of subjects: 0
Study 37384960 — intervention group
Group type: EXPERIMENTAL
Intervention: Safer Kids
Number of subjects: 112
Study 37384960 — intervention group
Group type: COMPARATOR
Intervention: Intervention as Usual (IAU)
Number of subjects: 112
Study 37385070 — intervention group
Group type: EXPERIMENTAL
Intervention: Early relapse (mTNBC)
Number of subjects: 881
Study 37385070 — intervention group
Group type: COMPARATOR
Intervention: Late relapse (mTNBC)
Number of subjects: 881
Study 37385161 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer mentor-led educational intervention
Number of subjects: 30
Study 37385161 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for mentors
Number of subjects: 30
Study 37385272 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant VWF, 40 IU/kg over 5-10 min on day 1
Number of subjects: 39
Study 37385272 — intervention group
Group type: COMPARATOR
Intervention: Oral tranexamic acid 1300 mg three times daily on days 1-5
Number of subjects: 39
Study 37385275 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 938
Study 37385275 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 938
Study 37385275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 938
Study 37385278 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide 50 mg
Number of subjects: 667
Study 37385278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 667
Study 37385279 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide 25 mg
Number of subjects: 1606
Study 37385279 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide 50 mg
Number of subjects: 1606
Study 37385279 — intervention group
Group type: COMPARATOR
Intervention: Oral semaglutide 14 mg
Number of subjects: 1606
Study 37385280 — intervention group
Group type: EXPERIMENTAL
Intervention: Retatrutide
Number of subjects: 281
Study 37385280 — intervention group
Group type: COMPARATOR
Intervention: Dulaglutide 1.5 mg
Number of subjects: 281
Study 37385280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study 37385280 — intervention group
Group type: EXPERIMENTAL
Intervention: Retatrutide 0.5 mg
Number of subjects: 281
Study 37385280 — intervention group
Group type: EXPERIMENTAL
Intervention: Retatrutide 4 mg escalation
Number of subjects: 281
Study 37385280 — intervention group
Group type: EXPERIMENTAL
Intervention: Retatrutide 4 mg
Number of subjects: 281
Study 37385280 — intervention group
Group type: EXPERIMENTAL
Intervention: Retatrutide 8 mg slow escalation
Number of subjects: 281
Study 37385280 — intervention group
Group type: EXPERIMENTAL
Intervention: Retatrutide 8 mg fast escalation
Number of subjects: 281
Study 37385280 — intervention group
Group type: EXPERIMENTAL
Intervention: Retatrutide 12 mg escalation
Number of subjects: 281
Study 37385475 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-56136379 75 mg monotherapy
Number of subjects: 60
Study 37385475 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-56136379 250 mg monotherapy
Number of subjects: 60
Study 37385475 — intervention group
Group type: COMPARATOR
Intervention: Nucleos(t)ide analogue (NA) treatment
Number of subjects: 60
Study 37385583 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up (ABC) intervention
Number of subjects: 60
Study 37385583 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 60
Study 37385670 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37385675 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibroblast Activation Protein (FAP) assessment
Number of subjects: 0
Study 37385675 — intervention group
Group type: COMPARATOR
Intervention: Standard diagnostic methods
Number of subjects: 0
Study 37385724 — intervention group
Group type: EXPERIMENTAL
Intervention: SEA-CD40 administered intravenously at doses of 0.6, 3, 10, 30, 45, and 60 µg/kg in 21-day cycles.
Number of subjects: 67
Study 37385724 — intervention group
Group type: EXPERIMENTAL
Intervention: SEA-CD40 administered intravenously at doses of 10-30 µg/kg.
Number of subjects: 67
Study 37385724 — intervention group
Group type: EXPERIMENTAL
Intervention: SEA-CD40 monotherapy.
Number of subjects: 67
Study 37385747 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) - combination of aspirin and P2Y
Number of subjects: 0
Study 37385747 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37385828 — intervention group
Group type: EXPERIMENTAL
Intervention: imlifidase
Number of subjects: 15
Study 37385855 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 levels monitoring
Number of subjects: 170
Study 37385888 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderna/mRNA1273, AstraZeneca/AZD1222, Janssen/Ad26.COV2.S, Novavax/NVX-CoV2373 (vaccine)
Number of subjects: 114480
Study 37385888 — intervention group
Group type: EXPERIMENTAL
Intervention: Janssen/Ad26.COV2.S (vaccine)
Number of subjects: 114480
Study 37385888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114480
Study 37385905 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (SZC)
Number of subjects: 134
Study 37385905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 37385981 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage focal HIFU or cryotherapy (specific intervention details not provided)
Number of subjects: 168
Study 37385981 — intervention group
Group type: EXPERIMENTAL
Intervention: Model performance assessment
Number of subjects: 168
Study 37385995 — intervention group
Group type: EXPERIMENTAL
Intervention: Unecritinib 300 mg BID
Number of subjects: 147
Study 37385995 — intervention group
Group type: EXPERIMENTAL
Intervention: Unecritinib 100, 200, 300 mg QD and 200, 250, 300, 350 mg BID
Number of subjects: 147
Study 37386016 — intervention group
Group type: EXPERIMENTAL
Intervention: Milademetan (MDM2i) with low-dose cytarabine (LDAC)
Number of subjects: 16
Study 37386016 — intervention group
Group type: EXPERIMENTAL
Intervention: Milademetan (MDM2i) with low-dose cytarabine (LDAC)±venetoclax
Number of subjects: 16
Study 37386034 — intervention group
Group type: EXPERIMENTAL
Intervention: NPD group (n=28)
Number of subjects: 61
Study 37386034 — intervention group
Group type: COMPARATOR
Intervention: non-NPD group (n=33)
Number of subjects: 61
Study 37386363 — intervention group
Group type: EXPERIMENTAL
Intervention: Young-old group (65-74 years)
Number of subjects: 62
Study 37386363 — intervention group
Group type: COMPARATOR
Intervention: Old-old group (75-84 years)
Number of subjects: 62
Study 37386368 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy-led triage
Number of subjects: 638
Study 37386368 — intervention group
Group type: COMPARATOR
Intervention: Standard care assessment by an orthopedic surgeon
Number of subjects: 638
Study 37386462 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 144
Study 37386462 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 144
Study 37386462 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 144
Study 37386462 — intervention group
Group type: COMPARATOR
Intervention: Control (initial phase weeks 0-6)
Number of subjects: 144
Study 37386462 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic-naïve and previously medicated participants
Number of subjects: 144
Study 37386473 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomechanical-based Tai Chi training program, practiced thrice a week for 12 weeks.
Number of subjects: 40
Study 37386473 — intervention group
Group type: COMPARATOR
Intervention: Regular physical activity (PA) for at least 60 minutes, thrice a week for 12 weeks.
Number of subjects: 40
Study 37386485 — intervention group
Group type: EXPERIMENTAL
Intervention: Markers of collagen turnover (PRO-C6 and C3M)
Number of subjects: 300
Study 37386512 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical Bayesian dynamic model (HBDM) applied to Motor Activity Log (MAL) data from DOSE trial participants (0, 15, 30, or 60-h dose condition).
Number of subjects: 135
Study 37386512 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical Bayesian dynamic model (HBDM) applied to Motor Activity Log (MAL) data from EXCITE trial participants (60-h dose, immediate or delayed condition).
Number of subjects: 135
Study 37386512 — intervention group
Group type: EXPERIMENTAL
Intervention: Forecasting MAL of new participants using HBDM.
Number of subjects: 135
Study 37386512 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical modeling for early training prediction.
Number of subjects: 135
Study 37386512 — intervention group
Group type: COMPARATOR
Intervention: Comparison of HBDM with static regression models and simpler dynamic models.
Number of subjects: 135
Study 37386519 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral spinal anesthesia with 40 mg of hyperbaric prilocaine (Group A)
Number of subjects: 132
Study 37386519 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia with mepivacaine (Group B)
Number of subjects: 132
Study 37386580 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid responsiveness assessment using stroke volume variation (SVV)
Number of subjects: 57
Study 37386580 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic function parameters (including mitral E/e' ratio)
Number of subjects: 57
Study 37386582 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block (DNMB) with rocuronium bolus at 1.2 mg/kg and maintenance dose of 0.3-0.6 mg/kg/h
Number of subjects: 50
Study 37386582 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular block (MNMB) with rocuronium bolus at 0.6 mg/kg and maintenance dose in boluses of 0.15-0.25 mg/kg
Number of subjects: 50
Study 37386582 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block (DNMB)
Number of subjects: 50
Study 37386582 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular block (MNMB)
Number of subjects: 50
Study 37386594 — intervention group
Group type: EXPERIMENTAL
Intervention: SPMs supplementation (n=23 subjects)
Number of subjects: 51
Study 37386594 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=28 subjects)
Number of subjects: 51
Study 37386744 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect revascularization surgery (encephaloduroarteriosynangiosis - EDAS)
Number of subjects: 123
Study 37386744 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect revascularization surgery (EDAS)
Number of subjects: 123
Study 37386752 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized healing abutment with connective tissue graft (CTG)
Number of subjects: 32
Study 37386752 — intervention group
Group type: COMPARATOR
Intervention: Customized healing abutment without connective tissue graft (CTG)
Number of subjects: 32